The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

MicroPort CardioFlow Medtech Corp. ( ($HK:2160) ) just unveiled an update. MicroPort CardioFlow Medtech Corporation announced the formal release ...

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a ...

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

NEW YORK CITY -- Mitral valve technology developers were urged to go back to the drawing board due to current-generation devices not meeting the needs of enough patients with mitral regurgitation (MR) ...

LONDON — Opinions about the relative value of interventions to control mitral regurgitation secondary to heart failure might be altered by two large randomized trials. The RESHAPE-HF2 trial showed ...

Jenscare Scientific Co. Ltd. Class H ( ($HK:9877) ) has provided an announcement. Jenscare Scientific has submitted a registration application for ...

UPMC Heart and Vascular Institute in Central Pa. today announced that its doctors treated a patient using the Half Moon Medical transcatheter mitral repair technology (Half Moon TMVr System). This ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- The global heart valve repair and replacement devices market size is estimated to grow by USD 2.58 billion from 2024-2028, according to Technavio. The market is ...

ATLANTA (Reuters) - An experimental, minimally invasive technique to repair the most common type of heart valve problem proved to be far safer and nearly as effective as open heart surgery, meeting ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...